Complete Genomics seals $45M for cheaper gene sequencing

Complete Genomics seals $45M for cheaper gene sequencing

Complete Genomics, provider of supposedly cheaper and faster DNA sequencing services, has raised $45 million in a fourth round of funding — a huge amount for a biotech company in today’s economic environment. Based in Mountain View, Calif., the company says it will be able… Continue Reading

DNA-decoding startup 23andMe raises another $2.6M from Google

DNA-decoding startup 23andMe raises another $2.6M from Google

Google has invested another $2.6 million inĀ 23andMe, the genetics startup co-founded by Anne Wojcicki (who’s married to Google co-founder Sergey Brin). The funding was revealed in a regulatory filing first spotted by Silicon Alley Insider.

Mountain View, Calif.-based 23andMe charges a $399 fee to provide customers… Continue Reading

23andMe gets $11M boost to decode your DNA

23andMe gets $11M boost to decode your DNA

23andMe, the company that deciphers consumers’ genomes for them, has raised $11 million of an anticipated $24.26 million second round of capital. The company was cofounded by Anne Wojcicki, wife of Google co-founder Sergey Brin.

The firm didn’t disclose its recent investors, but peHub noted this… Continue Reading

Yahoo, LinkedIn execs join personal genomics startup 23andMe

Yahoo, LinkedIn execs join personal genomics startup 23andMe

23andMe, the startup that helps consumers decode their genetic information, has announced two big hires: former LinkedIn Vice President of Revenue and Customer Operations, Sarah Imbach, is the Mountain View, Calif. startup’s new chief operating officer; former Yahoo User Experience Vice President, Larry Tesler, has… Continue Reading

Roundup: Six Apart launches ad network, Microsoft acquires Xobni…maybe and more

Roundup: Six Apart launches ad network, Microsoft acquires Xobni…maybe and more

Here’s the latest action:

Six Apart evolves into an ad network — The blogging company behind MovableType, TypePad and Vox is offering a new advertising program which will give publishers more control over ads and revenue from their sites. The company claims its ad network will be… Continue Reading

23andMe allows a peek at its genomics service, minus the $999 fee

23andMe allows a peek at its genomics service, minus the $999 fee

23andMe — the Google-backed startup that scans your genome for disease-risk factors and other information, now lets anyone see how the service works without first charging $999 for the privilege. My first impression: It packs a tremendous amount of information into clean, uncluttered pages that… Continue Reading

23andMe makes genomics personal — and slick

23andMe makes genomics personal — and slick

(UPDATED: See below.)

As I discussed a few weeks ago with respect to deCODEme — a “personal genomics” service hurriedly launched last November by Iceland’s deCODE Genetics in an apparent attempt to beat 23andMe to market (it succeeded by a day or so) — these sorts of… Continue Reading

23andMe’s European vacation and other personal-genomics notes

23andMe’s European vacation and other personal-genomics notes

(UPDATED: Added links from Davos. Also, an earlier version of this post originally appeared at the end of this item.)

While I’ve been diving into deCODEme’s surprisingly spotty personal-genomics service, 23andMe has been whooping it up in Europe. The startup launched its consumer gene-scanning service there and… Continue Reading

deCODEme and its questionable disease-risk predictions

deCODEme and its questionable disease-risk predictions

(UPDATED: Original final paragraphs on 23andMe broken out as a separate post here.)

A few days ago, I noted that deCODEme, the personal-genomics spinoff of Iceland’s deCODE Genetics, looks to be offering disease-risk predictions based on surprisingly thin evidence. I looked into it a little more deeply,… Continue Reading

deCODEme’s underwhelming personal-genomics service

deCODEme’s underwhelming personal-genomics service

(UPDATED: See below.)

Personal-genomics vendors like 23andMe and deCODEme, which promise to give ordinary individuals a peek at their genetic inheritance, have received a ton of press attention since they launched last November (not least of all from us — see here and here for starters). Unless… Continue Reading

23andMe: Will the personal-genomics company need Big Pharma to make money?

23andMe: Will the personal-genomics company need Big Pharma to make money?

23andMe held its official launch today, as expected, and in the process managed to address a few of the nagging questions that remained after I reviewed its service over the weekend. “Addressed” is definitely the operative word here, though, because firm answers are still in… Continue Reading

23andMe lets you search and share your genome — today

23andMe lets you search and share your genome — today

(UPDATED: See below.)

Personal genomics is finally here.

23andMe, the Google-backed startup that promises to let individuals search and share their personal genetic information, just unveiled its service on its Web site. (A formal announcement is planned for Monday. For links to our previous coverage, see the end… Continue Reading

Will 23andMe and Navigenics lock up your genome and charge you for the key?

Will 23andMe and Navigenics lock up your genome and charge you for the key?

Over the last few months, startups like 23andMe and Navigenics have attracted a fair bit of attention for promising to let ordinary people search through their own genomes to better understand their disease risk, genealogy and ancestry. (For our coverage, see the links at the… Continue Reading

Life sciences briefing: Thursday, Oct. 4, 2007

Life sciences briefing: Thursday, Oct. 4, 2007

Featured companies: 23andMe, APT Pharmaceuticals, Hyperion Therapeutics, Isis Biopolymer, Virogenomics

UPDATED at 10:30am PT.

APT Pharma raises $22M for transplant and heart drugs — Burlingame, Calif.’s APT Pharmaceuticals, a specialty pharma currently focused on a drug to fight organ-transplant rejection, raised $22 million in an extension of its first… Continue Reading

Complete Genomics and BioNanomatrix rev up the fast, cheap and out-of-control genome race

Complete Genomics and BioNanomatrix rev up the fast, cheap and out-of-control genome race

Things are starting to get crowded in the race to sequence entire human genomes quickly and relatively cheaply — usually meaning somewhere in the territory of $1,000 per genome, compared to the $100,000+ it costs with current technology. At least four startups have taken on… Continue Reading

Carry your genome around on your iPhone

Carry your genome around on your iPhone

What if you around your genome — the full details of your personal DNA — on your cellphone and compare it instantly to the DNA of a prospective dating partner simply by sharing over a WiFi connection?

That just one bizarre thought that comes to mind,… Continue Reading

Decoding 23andMe — Illumina spills the beans

Decoding 23andMe — Illumina spills the beans

First, it was self-described 23andMe investor Martin Varsavsky who spilled some early information about the secretive personal-genomics startup founded by Sergey Brin’s new wife, Anne Wojcicki, and now backed by Google and Genentech. (See our coverage here.) Now more details about 23andMe’s plans to help… Continue Reading

Craig Venter’s genome and our brave new world

Craig Venter’s genome and our brave new world

(UPDATED: See below.)

It’s finally all about him.

By “him,” of course, I mean J. Craig Venter, the iconoclastic scientist who had his entire genome sequenced, posted in a public database, and analyzed in a scientific paper published Monday in the online journal PLoS Biology. If for some… Continue Reading

Navigenics provides your genetic information, gets high-profile backing

Navigenics provides your genetic information, gets high-profile backing

Navigenics, a new secretive Silicon Valley company, wants to let you access your genetic information, so you can see what sort of diseases or sicknesses you may be prone to. It has backing from high-profile venture capital firms Kleiner Perkins and Sequoia Capital.

It joins another… Continue Reading

Personal-genetics startup Navigenics, a competitor to Google-backed 23andMe, unstealths

Personal-genetics startup Navigenics, a competitor to Google-backed 23andMe, unstealths

(UPDATED: See below.)

Navigenics, a new personal genetics startup with some serious backing, threw back the curtain over the weekend by unveiling its Web site. The Redwood Shores, Calif., startup says it aims to provide individuals with their genetic profiles and then to “arm” them with ways… Continue Reading